Status:
COMPLETED
Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Chronic Obstructive Pulmonary Disease (COPD)
Eligibility:
All Genders
40+ years
Phase:
PHASE3
Brief Summary
This study compared the safety and efficacy of indacaterol 150 µg taken once daily (o.d.) versus salmeterol 50 µg taken twice daily (b.i.d) in patients 40 years old or older with chronic obstructive p...
Eligibility Criteria
Inclusion
- Adults aged ≥ 40 years
- Diagnosis of chronic obstructive pulmonary disease (COPD) (moderate to severe as classified by the GOLD Guidelines, 2007) and:
- Smoking history of at least 10 pack years
- Post-bronchodilator forced expiratory volume in 1 second (FEV1) \< 80% and ≥ 30% of the predicted normal value at screening
- Post-bronchodilator FEV1/FVC (forced vital capacity) \< 70% at screening
Exclusion
- Patients who have received systemic corticosteroids for a COPD exacerbation in the 6 weeks prior to screening or during the run-in period
- Patients requiring long-term oxygen therapy (\> 15 h a day) for chronic hypoxemia
- Patients who have had a respiratory tract infection within 6 weeks prior to screening
- Patients with concomitant pulmonary disease
- Patients with a history of asthma
- Patients with diabetes Type I or uncontrolled diabetes Type II
- Any patient with lung cancer or a history of lung cancer
- Any patient with active cancer or a history of cancer with less than 5 years disease-free survival time
- Patients with a history of long QT syndrome or whose QTc interval (Fridericia's) measured at screening is prolonged
- Patients who have been vaccinated with live attenuated vaccines within 30 days prior to screening or during the run-in period
- Patients unable to successfully use a dry powder inhaler device or perform spirometry measurements
- Other protocol-defined inclusion/exclusion criteria applied to the study.
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
1123 Patients enrolled
Trial Details
Trial ID
NCT00821093
Start Date
January 1 2009
End Date
October 1 2009
Last Update
August 18 2011
Active Locations (144)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigator Site
Anniston, Alabama, United States, 36207-5710
2
Novartis Investigator Site
Fairhope, Alabama, United States, 36532
3
Novartis Investigator Site
Jasper, Alabama, United States, 35501
4
Novartis Investigator Site
Mobile, Alabama, United States, 36604